%0 Editorial
%T Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
%A Colombo N
%A Gadducci A
%A Landoni F
%A Lorusso D
%A Sabbatini R
%A Artioli G
%A Berardi R
%A Ceccherini R
%A Cecere SC
%A Cormio G
%A De Angelis C
%A Legge F
%A Lissoni A
%A Mammoliti S
%A Mangili G
%A Naglieri E
%A Petrella MC
%A Ricciardi GRR
%A Ronzino G
%A Salutari V
%A Sambataro D
%A Savarese A
%A Scandurra G
%A Tasca G
%A Tomao F
%A Valabrega G
%A Zavallone L
%A Pignata S
%J Gynecol Oncol
%V 175
%N 0
%D 2023 08 22
%M 37355448
%F 5.304
%R 10.1016/j.ygyno.2023.05.065
%X Standard treatment of newly diagnosed, advanced ovarian carcinoma (OC) consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently shown to significantly improve progression-free survival in the first-line setting. Some practical aspects of maintenance therapy, however, are still poorly defined.<BR>To provide guidance to clinicians in the selection of maintenance therapy for newly diagnosed, advanced ovarian carcinoma.<BR>A board of six gynecologic oncologists with expertise in the treatment of OC in Italy convened to address issues related to the new options for maintenance treatment. Based on scientific evidences, the board produced practice-oriented statements. Consensus was reached via a modified Delphi study that involved a panel of 22 experts from across Italy.<BR>Twenty-seven evidence- and consensus-based statements are presented, covering the following areas of interest: use of biomarkers (BRCA mutations and presence of homologous recombination deficiency); timing and outcomes of surgery; selection of patients eligible for bevacizumab; definition of response to treatment; toxicity and contraindications; evidence of synergy of bevacizumab plus PARP inhibitor. Two treatment algorithms are also included, for selecting maintenance therapy based on timing and outcomes of surgery, response to platinum-based chemotherapy and biomarker status. A score for the assessment of response to chemotherapy is proposed, but its validation is ongoing.<BR>We provide here consensus statements and treatment algorithms to guide clinicians in the selection of appropriate and personalized maintenance therapy in the first-line setting of advanced OC management.